Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial

Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial

ABSTRACT Aims/Introduction We conducted a 5 year post‐trial monitoring study of our previous randomized 24 week, open‐label, active‐controlled trial that showed beneficial effects of ipragliflozin on metabolic dysfunction‐associated steatotic liver disease (MASLD), identical to those of pioglitazone...

Full description

Bibliographic Details
Main Authors: Daisuke Ito, Satoshi Shimizu, Akifumi Haisa, Shinnosuke Yanagisawa, Kazuyuki Inoue, Daigo Saito, Takashi Sumita, Morifumi Yanagisawa, Yoshihito Uchida, Kouichi Inukai, Akira Shimada
Format: Article
Language:English
Published: Wiley 2024-09-01
Series:Journal of Diabetes Investigation
Subjects:
Metabolic dysfunction‐associated steatotic liver disease
Non‐alcoholic fatty liver disease
Sodium‐glucose cotransporter 2 inhibitors
Online Access:https://doi.org/10.1111/jdi.14246

Internet

https://doi.org/10.1111/jdi.14246

Similar Items